Exome Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Exome Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.37M	Sell	18,359 -49,133	-73%	-$3.44M	0.84%	43
2026 Q1	$5.01M	Sell	67,492 -13,231	-16%	-$959K	2.59%	10
2025 Q4	$6.17M	Sell	80,723 -52,364	-39%	-$3.44M	2.95%	9
2025 Q3	$6.91M	Sell	133,087 -22,446	-14%	-$1.09M	4.19%	3
2025 Q2	$6.72M	Sell	155,533 -9,963	-6%	-$362K	4.99%	2
2025 Q1	$5.72M	Sell	165,496 -81,204	-33%	-$2.74M	5.09%	1
2024 Q4	$6.77M	Buy	246,700 +35,700	+17%	+$923K	5.09%	1
2024 Q3	$5.37M	Buy	211,000 +132,093	+167%	+$3.47M	3.63%	3
2024 Q2	$2M	Buy	78,907 +30,100	+62%	+$823K	1.78%	28
2024 Q1	$1.51M	Sell	48,807 -16,306	-25%	-$555K	1.29%	35
2023 Q4	$2.63M	Buy	+65,113	New	+$1.96M	2.6%	15

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Exome Asset Management's BBIO Position: Q2 2026 in Review

Exome Asset Management reduced its BridgeBio Pharma (BBIO) stake by 73% in Q2 2026, selling an estimated $3.44M and leaving 18,359 shares worth $1.37M. The position accounts for 0.84% of the portfolio, ranked #43.

Exome Asset Management first reported a position in BBIO in Q4 2023 and has held it in 11 quarters since. The position peaked at $6.91M in Q3 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Exome Asset Management held 18,359 shares of BridgeBio Pharma worth $1.37M as of Q2 2026.
Exome Asset Management sold 49,133 BridgeBio Pharma shares in Q2 2026, an estimated $3.44M.
BridgeBio Pharma made up 0.84% of Exome Asset Management's portfolio in Q2 2026, its #43 holding.
Exome Asset Management first reported a position in BridgeBio Pharma in Q4 2023 and has held it in 11 quarters since.
Exome Asset Management's BridgeBio Pharma position peaked at $6.91M in Q3 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.